Three studies presented at the American Society of Hematology (ASH) 58th Annual Meeting held in San Diego, California, US highlight the use of chimeric antigen receptor (CAR) T cell therapy for the treatment of refractory adult and paediatric lymphoma and leukaemia.
Findings from a phase III trial show that the anti-CD30 antibody-drug conjugate, brentuximab vedotin (BV), is superior to methotrexate or bexarotene in the efficacy endpoint of overall response rate (ORR) lasting ≥4 months in the treatment of cutaneous T cell lymphoma (CTCL).
Cancer patients who have undergone successful treatment may have increased risk of developing therapy-related myeloid neoplasms (t-MNs), a fatal form of secondary malignancy, even after years of successful treatment, according to a recent study presented at the ASH 58th Annual Meeting in San Diego, California, US.
Lenalidomide maintenance therapy reduces the risk of progression by more than 80 percent in patients with high-risk chronic lymphocytic leukaemia (CLL) who responded to first-line chemoimmunotherapy, interim results of the phase III CLL M1 study have shown.
Obinutuzumab reduces the risk of disease progression by about one-third in patients with advanced follicular lymphoma (FL) compared with rituximab, interim results of the phase III GALLIUM study have shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacy - Malaysia digital copy today!
A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated.
Pearl Toh spoke with Dr Teh Ming Ming, senior consultant at the Department of Endocrinology, Singapore General Hospital (SGH), on the major challenges of diagnosing and managing diabetes in primary care, in conjunction with the World Diabetes Day on 14 November. Awareness of the symptoms of diabetes is important, and patients should be empowered to manage their conditions.
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.